Home Sitemap Contact us Accessibility Statement Top of the page
  • Aerivio® Spiromax®

    Aerivio® Spiromax®


Prescribing Aerivio Spiromax®

Aerivio Spiromax® (salmeterol xinafoate/fluticasone propionate) is a dry powder inhaler for the management of severe asthma and COPD.1

Available in one strength of 50/500 mcg; it is licensed for adults aged 18 years and over.1

Therapeutic indications 


Aerivio Spiromax® is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:

  • patients not adequately controlled on a lower strength corticosteroid combination product, or
  • patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.1

Chronic Obstructive Pulmonary Disease (COPD)

Aerivio Spiromax® is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.1

The launch of Aerivio Spiromax® extends the treatments available from the Spiromax® inhaler, following the launch of DuoResp Spiromax® (budesonide/formoterol) in 2014.

Aerivio Spiromax® brings together the effective combination of salmeterol/fluticasone in a device that’s ready to use in one flip of the cover

The Spiromax® device

The Spiromax® inhaler has been designed to be uncomplicated and user-friendly.

Evidence suggests that inhalers which are easier for healthcare professionals to train, and for patients to use, can help to ensure correct inhaler technique and reduce non-adherence.2

In a qualitative study on patient and healthcare professional device preferences, the Spiromax® device was preferred by patients and healthcare professionals.*

  • Of 80 patients: 70% preferred Spiromax® over their current device3
  • Of 181 HCPs: 78% considered Spiromax® to be easier to teach than their currently used device3

Poor inhaler technique can lead to poor control of asthma and COPD. This may result in reduced lung deposition of inhaled medicines,4 and increase symptoms and exacerbations.5,6 These factors can also contribute to increased appointments and emergency hospital admissions.

The Spiromax® device has shown consistent dose delivery in real-word conditions**7 and provides dose confirmation to patients through the lactose taste and precise dose indicator. It requires no co-ordination of actuation or inhalation.7,8

In addition to the healthcare professional and patient benefits, Aerivio Spiromax® also provides cost-savings vs. Seretide® (salmeterol/fluticasone) Accuhaler® 50/500 mcg.9

*Patients currently used Turbohaler® or Accuhaler®, all healthcare professionals had experience in the regular treatment of asthma and COPD patients.
**Only DuoResp Spiromax® (budesonide/formoterol) studied

About Aerivio Spiromax®

About Aerivio Spiromax®

Demonstration video

Download Video: MP4, WebM Ogv

Marketing Authorisation

Teva B.V.
Swensweg 5,
2031 GA Haarlem

Marketing Authorisation number(s)

  • EU/1/16/1122/001
  • EU/1/16/1122/002

Resources for Aerivio Spiromax®

You can ask a question, request to see a representative from Teva, or report a side effect.

Ask a Question Request a Rep Report Suspected Side Effect

Medicine supporting documentation for Aerivio Spiromax®
  • Summary of Product Characteristics - Aerivio Spiromax® 50 micrograms/500 micrograms inhalation powder
    View Document >
  • Patient Information Leaflet
    View Document >
  • Abbreviated Prescribing Information - Aerivio Spiromax®
    View Document >

Teva's Respiratory Educational Programme

Let's Talk Respiratory is our educational programme of supportive materials, resources and some of the latest news in respiratory for both you and your patients. Our aim is to support you and encourage you, help empower patients and to make a real difference to the lives of those living with asthma and COPD.

1. Aerivio Spiromax® Summary of Product Characteristics

2. Price D et al. Resp Med 2013; 107:37-46

3. Plusa T, Bijos P. Int. Rev. Allergol Clin Immunol Family Med 2015; 21: 21-4

4. Giraud V, Roche N. Eur Resp J 2002; 19:246-251

5. Melani AS et al. Resp Med 2011; 105:930-938

6. Kemp L et al. Clinicoecon Outcomes Res 2010; 2:75-85

7. Canonica G et al. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015; 28(5): 309-19.

8. Chrystyn H et al. Int J Pharm, 2015; 491: 268-76.

9. MIMS. Available at: http://www.mims.co.uk/drugs/respiratory-system/asthma-copd/seretideaccuhaler. Last accessed: February 2017.

Teva UK Limited

Are you a healthcare professional?

To access this section of the Teva UK Limited website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
To understand why that is - please visit: Working in a regulated environment

Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.

I am a